M
Margaret C. Fang
Researcher at University of California, San Francisco
Publications - 154
Citations - 14247
Margaret C. Fang is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Atrial fibrillation & Stroke. The author has an hindex of 36, co-authored 131 publications receiving 12758 citations. Previous affiliations of Margaret C. Fang include Stanford University & Harvard University.
Papers
More filters
Journal ArticleDOI
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
Walter N. Kernan,Bruce Ovbiagele,Henry R. Black,Dawn M. Bravata,Marc I. Chimowitz,Michael D. Ezekowitz,Margaret C. Fang,Marc Fisher,Karen L. Furie,Donald V. Heck,S. Claiborne Johnston,Scott E. Kasner,Steven J. Kittner,Pamela H. Mitchell,Michael W. Rich,DeJuran Richardson,Lee H. Schwamm,John A. Wilson +17 more
TL;DR: In this paper, the authors provided evidence-based recommendations for the prevention of future stroke among survivors of ischemic stroke or transient ischemi-chemic attack, including the control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke.
Journal ArticleDOI
Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
John J. You,Daniel E. Singer,Patricia A. Howard,Deirdre A. Lane,Mark H. Eckman,Margaret C. Fang,Elaine M. Hylek,Sam Schulman,Alan S. Go,Michael Hughes,Frederick A. Spencer,Warren J. Manning,Jonathan L. Halperin,Gregory Y.H. Lip +13 more
TL;DR: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (CHADS(2) score of ≥ 2) and at lower levels of stroke risk, antithROMbotic treatment decisions will require a more individualized approach.
Journal ArticleDOI
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Daniel E. Singer,Gregory W. Albers,James E. Dalen,Margaret C. Fang,Alan S. Go,Jonathan L. Halperin,Gregory Y.H. Lip,Warren J. Manning +7 more
TL;DR: This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th Edition).
Journal ArticleDOI
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.
Margaret C. Fang,Alan S. Go,Alan S. Go,Yuchiao Chang,Leila H. Borowsky,Niela K. Pomernacki,Natalia Udaltsova,Daniel E. Singer +7 more
TL;DR: A simple 5-variable risk score was effective in quantifying the risk of warfarin-associated hemorrhage in a large community-based cohort of patients with atrial fibrillation.
Journal ArticleDOI
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel,Benjamin French,Scott E. Kasner,Julie A. Johnson,Jeffrey L. Anderson,Brian F. Gage,Yves Rosenberg,Charles S. Eby,Rosemary Madigan,Robert B. McBane,Sherif Z. Abdel-Rahman,Scott M. Stevens,Steven H. Yale,Emile R. Mohler,Margaret C. Fang,Vinay Shah,Richard B. Horenstein,Nita A. Limdi,James A.S. Muldowney,Jaspal S Gujral,Patrice Delafontaine,Robert J. Desnick,Thomas L. Ortel,Henny H. Billett,Robert C. Pendleton,Nancy L. Geller,Jonathan L. Halperin,Samuel Z. Goldhaber,Michael D. Caldwell,Robert M. Califf,Jonas H. Ellenberg +30 more
TL;DR: Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy and there was a significant interaction between dosing strategy and race.